Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Satellite Symposia webcasts


Watch the webcasts from our industry partners' Satellite Symposia.


Understanding the treatment landscape in pancreatic cancer    

Watch session

  • Updates on the strategy of treatment in pancreatic cancer in Asia    
    Teresa Macarulla
  • Treatment strategy for metastatic pancreatic ductal adenocarcinoma: Surgeon’s point of view    
    Sohei Satoi
  • Japanese real-world data of Nal-IRI+5-FU/LV and the impact of UGT1A1 polymorphisms on treatment outcomes    
    Kazuaki Harada
  • Role of Nal-IRI in second-line treatment: Japanese oncologist’s perspective    
    Masafumi Ikeda
  • Conclusion and Q&A  

Transforming the journey for HER2+ breast cancer patients 

Watch session   

  • Welcome and introduction    
    Christian Jackisch
  • Transforming the experience of patients with HER2+ BC with recent clinical trials of PH FDC SC  
     Shu Wang
  • Value of subcutaneous treatment options for the healthcare system: Introducing flexible care an opportunity to bring treatment closer to patients  
    Christian Jackisch
  • NCCS homecare: Delivering cancer care at home    
    Elaine Lim
  • Question & answers    
  • Closing remarks    
    Christian Jackisch

Exploring optimal management and treatment sequencing in NSCLC, HCC and RCC    

Watch session

  • Welcome and opening    
    Hwai Loong Kong
  • Current management of NSCLC in Asia Pacific    
    Thanyanan Baisamut (reungwetwattana)
  • What’s new in management of non-mutated NSCLC    
    Solange Peters
  • Defining optimal sequencing in HCC with evidence and experience-based discussion    
    Han Chong Toh
  • How can we further optimize the management of RCC patients    
    Marniza Binti Saad
  • Q&A and closing    
    Hwai Loong Kong, Solange Peters

Thermofisher Scientific and Janssen Pharmaceuticals
Riding the new waves of success: Latest strategies in the screening and management of NSCLC patients with EGFR exon 20 insertion mutations    

Watch session

  • Opening remarks    
    Ross Soo
  • Setting out the sail in advanced NSCLC: The role of comprehensive genomic testing in advanced NSCLC    
    Timothy Tay
  • Watching out for the tsunami: The burden of unmet need in advanced NSCLC patients with EGFR exon 20 insertion mutations    
    Ross Soo
  • Adjusting the sails in advanced NSCLC management: Treatment options for advanced NSCLC patients with EGFR exon 20 insertion mutations    
    Byoung Chul Cho
  • Panel discussion    
  • Closing remarks    
    Ross Soo


Astellas Pharma
The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin  

Watch session

  • Welcome and introduction    
    Alvin Wong
  • Treating la/mUC: Unmet needs and the rapidly evolving landscape    
  • Alvin Wong
  • Spotlight on the clinical value of enfortumab vedotin in la/mUC: A review of the EV-301 core data    
    Thomas Powles
  • Patient management strategies for la/mUC treatment with enfortumab vedotin: A clinical case discussion    
    Terence Friedlander
  • Panel discussion / Q&A    
  • Chair's summary: Identifying the right patient for enfortumab vedotin    
    Alvin Wong


The emerging treatment landscape of targeted therapy and personalized healthcare in lung cancer    

Watch session

  • Welcome and introduction    
    Stephen Liu
  • How can precision medicine and biomarkers testing improve patient journey?    
    Angela Takano
  • Evolving landscape of early-stage lung cancer treatment: IMpower010    
  • Stephen Liu
  • Navigating options for mNSCLC    
  • Ross Soo
  • Molecular tumors boards: Navigating through the complexity    
    Jee Hyun Kim
  • Panel discussion and Q&A    
  • Meeting close    
    Jee Hyun Kim   

Bristol Myers Squibb
The role of immuno-oncology in GI cancers: Best practice and clinical questions    

Watch session

  • Welcome and introduction    
    Matthew Chau Hsien Ng
  • Immunotherapeutic advances in the treatment of colorectal cancer    
    Takayuki Yoshino
  • Update on immuno-oncology for the treatment of gastric cancer    
    Taroh Satoh
  • Advances in immuno-oncology for esophageal cancer: First-line metastatic disease and earlier stages    
    Chih-Hung Hsu
  • Q&A and summary    
  • Close    
    Matthew Chau Hsien Ng

Bristol Myers Squibb
Integration of immuno-oncology into the perioperative MIUC treatment landscape    

Watch session

  • Welcome and introduction    
    Laurence Albiges
  • Assessment of the MIUC treatment landscape in 2022    
    Laurence Albiges
  • Evidence for use of immuno-oncology in the perioperative setting    
    Yiping Zhu
  • Integrating immuno-oncology approaches in the early MIUC treatment pathway    
    Eiji Kikuchi
  • Interactive multidisciplinary team meeting    
  • Q&A    
  • Summary and close    
    Laurence Albiges

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.